Aura Biosciences publishes preclinical data on AU-011 + checkpoint inhibitors at ASCO 2022

Aura Biosciences, Inc.

AU-011 combined with immune checkpoint inhibitors showed efficacy against primary tumors and distant metastases in murine models.
Data published as abstract e14544 in 2022 ASCO Annual Meeting proceedings (June 3-7, 2022).
Collaboration with Leiden University Medical Center: survival data suggest potent targeted cytotoxicity on local tumors and metastases.
Potential clinical application for choroidal melanoma and non-muscle invasive bladder cancer (NMIBC).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.